Dr. Kathy Gately
Clinical Senior Lecturer, Clinical Medicine
Biography
Dr. Kathy Gately graduated with a BSc from University College Dublin and a PhD from the Department of Biochemistry, National University of Ireland Galway in 2000. During her PhD she spent six months at the University of California Los Angeles. She then worked as a postdoctoral fellow in the Dept. of Haematology where she carried out research on the novel targeted agent Imatinib in CML patients. In 2004, Dr. Gately was appointed as a Clinical Lecturer with Prof. Ken O'Byrne in the Dept. of Clinical Medicine. She was instrumental in the establishment of the Lung Cancer Biobank which supports research and clinical trials within the Translational Oncology Research Group (TORG).The main focus of Dr. Gately's research group is (i) the identification of novel prognostic/predictive biomarkers and therapeutic targets to improve treatment options for patients with cancer (ii) elucidating mechanisms of resistance to targeted therapies, in particular PI3K and EGFR inhibitors (iii) the role of the liquid biopsy in cancer diagnosis and treatment. Dr. Gately delivers lectures to undergraduate students in Molecular Medicine as well as the MSc in Molecular Medicine and Translational Oncology. She is editor of a recent book entitled: "Lung Cancer: A Comprehensive Review" Nova Publishers 2013. Dr. Gately is currently leading a research collaboration with Inflection Biosciences Ltd, an Irish company developing targeted small molecule treatments for cancer. The research examines the effectiveness of a panel of the company's targeted PIM kinase inhibitors in the treatment of thoracic malignancy. In particular, solid tumours that have become resistant to other forms of treatment. This research is supported in part by an Innovation Partnership Program award from Enterprise Ireland (EI).
Publications and Further Research Outputs
Peer-Reviewed Publications
Bracken-Clarke D, Kapoor D, Baird AM, Buchanan PJ, Gately K, Cuffe S, Finn SP., Vaping and lung cancer - A review of current data and recommendations., Lung cancer (Amsterdam, Netherlands), 153, 2021, p11-20
Moore, G.; Lightner, C.; Elbai, S.; Brady, L.; Nicholson, S.; Ryan, R.; O'Sullivan, K.E.; O'Byrne, K.J.; Blanco-Aparicio, C.; Cuffe, S.; O'Neill, M.; Heavey, S.; Finn, S.P.; Gately, K. , Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC, Cancers, 13, (9), 2021, p2139-
Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S., PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer., Signal Transduct Target Ther., 5, (7), 2020
Malone T, Schäfer L, Simon N, Heavey S, Cuffe S, Finn S, Moore G, Gately K., Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer., Pharmacology and Therapeutics, 207, 2020
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium., Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort., Modern Pathology, 33, (5), 2020, p792 - 801
Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT, Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples., Journal of Translational Medicine, 18, (1), 2020, p[1-99]
Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N., Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells., Cancers, 11, (4), 2019
Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K., Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines., Scientific Reports, 8, (1), 2018, p1652-
Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S, ETOP Lungscape Consortium., Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project., Annals of oncology : official journal of the European Society for Medical Oncology, 29, (1), 2018, p200-208
Collins, D.M. and Gately, K. and Hughes, C. and Edwards, C. and Davies, A. and Madden, S.F. and O'Byrne, K.J. and O'Donovan, N. and Crown, J., Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines, Cellular Immunology, 319, 2017, p35-42
Hutchinson RA, Coleman HG, Gately K, Young V, Nicholson S, Cummins R, Kay E, Hynes SO, Dunne PD, Senevirathne S, Hamilton PW, McArt DG, Longley DB, IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer, Cell Death Discovery, 14, (3), 2017, p17050-
Adams, M.N. and Burgess, J.T. and He, Y. and Gately, K. and Snell, C. and Zhang, S.-D. and Hooper, J.D. and Richard, D.J. and O'Byrne, K.J., Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Nonâ"Small Cell Lung Cancer, Journal of Thoracic Oncology, 12, (7), 2017, p1071-1084
Cathcart M.-C, Useckaite Z, Drakeford C, Semik V, Lysaght J, Gately K, O'Byrne K.J, Pidgeon G.P, Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo, BMC Cancer, 16, (1), 2016, p707-
Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K, Targeting the fibroblast growth factor receptor family in cancer, Cancer Treatment Reviews, 46, 2016, p51 - 62
Burgess J.T, Bolderson E, Adams M.N, Baird A.-M, Zhang S.-D, Gately K.A, Umezawa K, O'Byrne K.J, Richard D.J, Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response, Cell Death and Disease, 7, (11), 2016, pe2469-
Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K, In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC, Oncotarget, 7, (48), 2016, p79526 - 79543
Barr, M.P., Gray, S.G., Gately, K., (...), Pidgeon, G.P., O'Byrne, K.J., Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer, Molecular Cancer, 14, (1), 2015, p45-
O'Callaghan DS, Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer., European Respiratory Journal, 46, (6), 2015, p1762 - 1772
Elamin YY et al, Thymidine phosphorylase in cancer; enemy or friend?, Cancer Microenvironment, 9, (1), 2015, p33 - 43
Cathcart MC, Gately K, Cummins R, Drakeford C, Kay EW, O'Byrne KJ, Pidgeon GP, Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer., Biochimica et biophysica acta, 1842, (5), 2014, p747-55
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA, Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9, (11), 2014, p1675-84
Heavey S, O'Byrne KJ, Gately K, Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC., Cancer treatment reviews, 40, (3), 2014, p445-56
Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K, Strategic targeting of the PI3K-NF"B axis in cisplatin-resistant NSCLC., Cancer biology & therapy, 15, (10), 2014, p1367-77
Shikhrakab H, Elamin YY, O'Brien C, Gately K, Finn S, O'Byrne K, Osman N, Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience., Irish medical journal, 107, (7), 2014, p201-4
Barr M, Souan L, MacGabhann P, Muller J, Al-Ashhab M, Jasser M, Hamza K, Al-Hassoon S, Kuhn U, Infante D, Lawlor D, Kately K, Amireh E, O'Byrne K, Sughayer MA., The establishment of an ISO compliant cancer biobank for Jordan and its neighboring countries through knowledge transfer and training., Biopreservation and biobanking, 12, (1), 2014, p3-12
Al-Alao BS, Gately K, Nicholson S, McGovern E, Young VK, O'Byrne KJ, Prognostic impact of vascular and lymphovascular invasion in early lung cancer., Asian cardiovascular & thoracic annals, 22, (1), 2014, p55-64
Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, O'Byrne KJ, High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer., Clinical lung cancer, 15, (1), 2014, p58-66
Dowling P, Pollard D, Larkin A, Henry M, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarty M, O'Brien E, Morgan R, Clynes M, Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer., Molecular bioSystems, 2014
Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, Van Schaeybroeck S, Salto-Tellez M, Johnston PG, Fennell DA, Gately K, O'Byrne K, Cummins R, Kay E, Hamilton P, Stasik I, Longley DB, Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer., Cell death & disease, 4, 2013, pe951
Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L, Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma., Cancer Biology & Therapy, 14, (12), 2013, p1104 - 1112
Al-Alao BS, O'Callaghan DS, Gately K, Nicholson S, Coate LE, O'Connell F, McGovern E, O'Byrne KJ, Young VK, Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre., Irish journal of medical science, 182, (2), 2013, p217-25
Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K., Targeting nuclear factor-kappa B to overcome resistance to chemotherapy., Frontiers in oncology, 3, 2013, p120
Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M, RanGTPase: a candidate for Myc-mediated cancer progression., Journal of the National Cancer Institute, 105, (7), 2013, p475-88
Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K, The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC., Journal of clinical pathology, 65, (1), 2012, p1-7
Gately K, Al-Alao B, T Dhillon Mauri F, Cuffe S, Seckl M, O'Byrne K, Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study., Lung cancer (Amsterdam, Netherlands), 75, (2), 2012, p217-22
Gately K, Collins I, Forde L, Al-Alao B, Young V, Gerg M, Feuerhake F, O'Byrne K, A role for IGF-1R-targeted therapies in small-cell lung cancer?, Clinical lung cancer, 12, (1), 2011, p38-42
Gately K, Kerr K, O'Byrne K, Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis., Methods in molecular biology (Clifton, N.J.), 784, 2011, p139-53
Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA, PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer., The Journal of pathology, 224, (4), 2011, p564-74
Cathcart MC, Gray SG, Baird AM, Boyle E, Gately K, Kay E, Cummins R, Pidgeon GP, O'Byrne KJ, Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer., Cancer, 117, (22), 2011, p5121-32
Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP, Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer., Molecular cancer, 10, 2011, p25
Pirker R, Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop., Journal of Thoracic Oncology, 2010
Field JK, Liloglou T, Niaz A, Bryan J, Gosney JR, Giles T, Brambilla C, Brambilla E, Vesin A, Timsit JF, Hainaut P, Martinet Y, Vignaud JM, Thunnissen FB, Prinsen C, Snijders PJ, Smit EF, Sozzi G, Roz L, Risch A, Becker HD, Elborn JS, Magee ND, Montuenga LM, Pajares MJ, Lozano MD, O'Byrne KJ, Harrison DJ, Niklinski J, Cassidy A, EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration., The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, 34, (6), 2009, p1477-86
Wilson, TR, Redmond, KM, McLaughlin, KM, Crawford, N, Gately, K, O'Byrne, K, Le-Clorrenec, C, Holohan, C, Fennell, DA, Johnston, PG, Longley, DB, Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing, CELL DEATH AND DIFFERENTIATION, 16, (10), 2009, p1352-1361
Gray, SG, Al-Sarraf, N, Baird, AM, Gately, K, McGovern, E, O'Byrne, KJ, Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells., Clinical lung cancer, 9, (6), 2008, p367-374
Al-Sarraf, N., Gately, K., Lucey, J., Wilson, L., McGovern, E., Young, V., Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: Analysis of 1145 lymph nodes, Lung Cancer, 60, (1), 2008, p62-68
Al-Sarraf, N., Gately, K., Lucey, J., Aziz, R., Doddakula, K., Wilson, L., McGovern, E., Young, V., Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases, European Journal of Cardio-thoracic Surgery, 34, (4), 2008, p892-897
Al-Sarraf, N., Gately, K., Lucey, J., Wilson, L., McGovern, E., Young, V., Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer, Clinical Lung Cancer, 9, (1), 2008, p39-43
Al-Sarraf, N., Aziz, R., Gately, K., Lucey, J., Wilson, L., McGovern, E., Young, V., Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography, European Journal of Cardio-thoracic Surgery, 33, (1), 2008, p104-109
Al-Sarraf, N., Aziz, R., Doddakula, K., Gately, K., Wilson, L., McGovern, E., Young, V., Factors causing inaccurate staging of mediastinal nodal involvement in non-small cell lung cancer patients staged by positron emission tomography, Interactive Cardiovascular and Thoracic Surgery, 6, (3), 2007, p350-353
Doddakula, K., Al-Sarraf, N., Gately, K., Hughes, A., Tolan, M., Young, V., McGovern, E., Predictors of acute renal failure requiring renal replacement therapy post cardiac surgery in patients with preoperatively normal renal function, Interactive Cardiovascular and Thoracic Surgery, 6, (3), 2007, p314-318
Duggan, E., Caraher, E., Gately, K., O'Dwyer, M., McGovern, E., Kelleher, D., McManus, R., Ryan, T., Tumor necrosis factor-" and interleukin-10 gene expression in peripheral blood mononuclear cells after cardiac surgery, Critical Care Medicine, 34, (8), 2006, p2134-2139
S. R. McCann, K. Gately, E. Conneally and M. Lawler, Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML, Blood, 101, (3), 2003, p1200-1
Gately, K., McElwaine, S., O'Connor, L., McCann, S., Hollywood, D., Cotter, T., Lawler, M., In vitro treatment of CML cells with antisense oligonucleotides against BCR-ABL; Requirement for an efficient delivery system, Blood, 96, (11 PART II), 2000
Non-Peer-Reviewed Publications
Kathy Gately, Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer, Scientific Reports, 2020
kathy gately, Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer, Scientific Reports, 2020
Kathy Gately, Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer, Scientific Reports, 2020
Gaule P, Dasatinib, Cancers, 2019
Gately K, Advancing the treatment of non-small cell lung cancer - a combination approach, Cancer Professional, 2018
Kathy Gately, Lung Cancer : A Comprehensive Overview, First, New York U.S., Nova Science Publishers Inc, 2013
Research Expertise
Recognition
Memberships
AACR
ETOP
BTOG
ESBB
IASLC
ESMO
Irish Thoracic Society (ITS)
ERS